-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga·01/07/2026 20:27:29
語音播報
UBS analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ:ORKA) with a Buy rating and announces Price Target of $50.